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BACKGROUND
• Atopic dermatitis (AD) is a complex, immune-mediated, chronic inflammatory skin disease characterized by pruritus, 1, 2 which presents in moderate form in 20-37% of patients, and in severe form in 10-34% of patients. 3, 4 • The clinical course and presentation of AD is heterogeneous. 5 While approximately 85% of patients first develop AD in infancy 1, 6 with spontaneous resolution during childhood in a large proportion, 7, 8 AD can continue as a chronic condition that extends into adulthood for the substantial remaining number of patients. 9.10 • Worldwide prevalence rates of 2-10% have been estimated for adult AD, presenting as either adult-onset or as persistent or recurrent AD in adulthood continuing from its initial infant/childhood presentation. [11] [12] [13] • AD carries substantial patient burden due to associated outcomes such as sleep disturbances, functional impairment, depression, anxiety, and reduced overall health-related quality of life (HRQoL), particularly in those with higher levels of severity. 1, [14] [15] [16] -In adults, AD can create further burden via impairments to work productivity and activity. 14 • As current treatment options are limited, AD management remains challenging and many patients are left with poor disease control. First-line topical corticosteroids provide limited efficacy in moderate and/or severe AD, 17 while systemic immunomodulators such as oral corticosteroids are reserved for refractory cases 18, 19 due to their lack of evidence of safety and efficacy.
• There is insufficient knowledge on the character and extent of uncontrolled AD and patient burden, especially among adults with moderate and/or severe disease. A clearer understanding of their unmet medical needs, especially in real-world settings, is critical for guiding clinical decision-making in this segment of the patient population.
OBJECTIVE
• To characterize unmet medical needs among adults with a history of moderate and severe AD in the United Kingdom (UK), Germany, and France.
METHODS
• AD severity, disease control and patient burden were established on data obtained from the 2014 Adelphi AD Disease Specific Programme (DSP), a cross-sectional real-world survey that captured data from clinical and patient perspectives. 20, 21 • The current analysis examines AD clinical data reported by physicians from the UK (n=136), Germany (n=134), and France (n=137) and disease burden data by their consulting adult patients with a history of moderate and/or severe AD.
• The screening and recruitment of physicians reflected nationally representative samples subject to meeting the DSP inclusion criteria for physicians and patients.
• Patients provided consent for anonymized and aggregated results to be published.
• The sample of physicians practicing in the UK, Germany and France comprised primary care physicians (PCPs) (n=132), dermatologists (n=254), and allergists/immunologists (n=21) with active involvement in AD management.
• All physicians prospectively completed Patient Record Forms (PRFs) for up to five sequentially recruited patients; specialists additionally provided two further prospective PRFs for patients specifically receiving systemic immunosuppressant therapy.
Clinical data
• The physician-completed PRFs captured:
-physician-rated severity based on their subjective definitions of mild, moderate and severe AD -disease characteristics: body surface area (BSA) affected, current flare status, phase in life of disease onset (e.g. infancy, childhood, adolescence or adulthood) and disease state (e.g. improving, stable, deteriorating, changeable)
-the Eczema Area and Severity Index (EASI) score assessing AD via including body region involvement, area score, and severity scores 22 -treatment(s) administered -physician dissatisfaction with current AD control evaluated on a 1-7 scale (1=extremely dissatisfied, 7=extremely satisfied) with 1-3 classified as dissatisfied.
• Patients were categorised as having uncontrolled AD, based on any one or combination of the following criteria:
-currently flaring AD -deteriorating or changeable AD -physician dissatisfaction with current control.
• All others were categorised as controlled AD.
Patient-reported outcomes
• Patients completed the following patient-reported outcome (PRO) measures on Patient Self-Completed (PSC) forms:
-the Dermatology Life Quality Index (DLQI) 23 a dermatology-specific measure that assesses the impact of skin conditions on HRQoL over a 1-week recall period; higher scores indicating greater impact of symptoms on HRQoL -the Work Productivity and Impairment Questionnaire: Specific Health Problem (WPAI:SHP), a measure that determines overall AD-related work impairment over the last 7 days 24,25
-the EuroQoL EQ-5D 3-level questionnaire, (those responding at least some problems on domain were grouped into category, "problems on domain"), and a visual analog scale (VAS) score of patient health status, in addition utility scores were calculated based on country-specific tariffs.
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• Descriptive analyses of outcomes were performed using Stata Statistical Software: Release 14 (StataCorp LP, College Station, TX).
RESULTS

Patient demographics
• A total of 1965 (n=664 UK, n=641 Germany, n=660 France) adult patients with a history of moderate and/or severe AD were included in the study.
• Across countries and severities mean patient ages ranged from 33.6-41.7; 42.4-54.7% were female; and 65.0-87.8% were employed ( Table 1) .
Clinical characteristics by disease severity
• The majority of patients in each of the three countries (54.5% in the UK; 66.3% in Germany; 54.1% in France) had moderate AD based on physician subjective severity assessment at the time the survey was completed.
• Mean number of years since AD diagnosis for the cohorts ranged from 11.3-16.7 (mild), 7.4-15.0 (moderate), and 10.5-16.6 (severe) ( Table 1 ).
• Disease onset varied across country cohorts ( Table 1 ).
• Mean EASI scores ranged from 3.4-4.9 in patients with mild AD, 5.7-10.0 in patients with moderate AD, and 18.8-22.7 in patients with severe AD (Table 1) .
AD control
• The overall prevalence of uncontrolled AD in the UK, Germany, and France ranged from 53.9-59.2% ( Table 1 ).
• 84.9-88.2% of severe patients were classified as currently experiencing uncontrolled AD (Figure 1 ).
• The lack of disease control despite current use of any systemic agent or phototherapy ranged between 42.3% in France to 54.6% in Germany (Figure 2 ).
Patient burden
• Mean EQ-5D index scores declined by AD severity from 0.92-0.94 for mild disease to 0.71-0.72 for severe disease ( Table 2) . Compared with the other domains on the EQ-5D, reports of at least some problems were most prevalent on domains of pain/discomfort and anxiety/depression, especially in the moderate and/or severe cohorts (39.7-62.5% for pain/discomfort and 28.7-68.0% for anxiety/depression, respectively).
• Overall work and activity impairment was numerically highest for the patients with severe AD ranging from 20.9% to 29.0% for work impairment due to AD and 25.5% to 26.8% for activity impairment due to AD ( Table 2 ).
• A majority of severe patients with uncontrolled AD across all 3 countries reported DLQI scores of greater than 10, the clinical threshold indicating a very large effect on a patient's life.
23
In the UK, where the rates were highest, up to 73.9% of such patients reported DLQI >10. (Figure 3) . 
CONCLUSIONS
• More than half of adults with AD in the UK, Germany, and France have poor disease control.
-The rate of uncontrolled disease is especially high among patients with moderate AD (55.5-69.8%) and severe AD (84.9-88.2%).
• A majority of patients with severe AD report a very large impact on their HRQoL.
-This concurs with reports of burden in other dermatological conditions such as psoriasis.
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• Patients with severe AD report substantial impairment in their ability to work normally.
• High rates of uncontrolled AD (and the corresponding patient burden) despite being treated suggest that the effectiveness of existing treatment options, including systemic therapies is limited. 
